Early Pharmacological Treatment of Type II SMA Patients Slows Scoliosis Progression Dr Riya Dave19 Dec 2023 8:00 PM ISTA recent study has shed new light on the potential impact of early pharmacological interventions on scoliosis progression in individuals with Type II...
Health Bulletin 09/November/2023 Roshni Dhar9 Nov 2023 4:32 PM ISTHere are the top health stories for the day:Australian woman passed away after using OzempicA 56-year-old Australian woman named Trish Webster passed...
Royalty Pharma to pay USD 1 billion for Roche SMA drug royalties Ruchika Sharma22 Oct 2023 10:00 AM ISTPTC said it plans to use the proceeds from the deal to pay back its debt from Blackstone Life Sciences and to fund planned operations.
Insud Pharma inaugrates Oligonucleotides Centre in India Ruchika Sharma17 Sept 2023 1:00 PM ISTThis new plant will be capable of producing a novel antisense Oligonucleotide for the treatment of Spinal Muscular Atrophy.
Roche Evrysdi gets CHMP recommendation for babies under two months old with spinal muscular atrophy Ruchika Sharma24 July 2023 3:30 PM ISTEvrysdi is currently approved in the EU for the treatment of patients aged two months or older,
Kerala: Doctors at MCH perform spine surgery on 14-year-old SMA patient Kajal Rajput29 May 2023 1:00 PM ISTThiruvananthapuram: In a relief for Spinal Muscular Atrophy patients, a government medical college in Kerala has launched an innovative surgery to...
EMA seeks to issue guidance on liver damage from Novartis gene therapy Zolgensma Ruchika Sharma15 Jan 2023 12:15 PM ISTThe drug won conditional EU approval during early 2020 and it costs more than $2 million per patient
Zolgensma gene therapy caused two fatalities from liver failure, reports Novartis Ruchika Sharma14 Aug 2022 2:00 PM ISTBasel: Novartis AG on Thursday reported two patient fatalities due to acute liver failure following treatment with Zolgensma gene therapy used to...
Novartis donates Rs 16 crore drug to 23 month old Spinal Muscular Atrophy Type 1 patient MD Bureau8 Aug 2022 4:16 PM ISTAccording to Praveen, they had registered their daughter under Managed Access Programme of Novartis and they received the information that the company...
Roche gets USFDA nod for spinal muscular atrophy therapy Evrysdi for babies below 2 months Ruchika Sharma31 May 2022 4:02 PM ISTOf the babies with 2 or 3 copies of the SMN2 gene (n=6), 100% were able to sit after one year of treatment with Evrysdi, 67% could stand and 50% of...
Once-Daily Risdiplam beneficial in patients with Types 2 and 3 SMA: Lancet Dr. Shravani Dali19 Jan 2022 9:00 AM ISTOnce-Daily Risdiplam is beneficial in patients with Types 2 and 3 spinal muscular atrophy (SMA), according to a recent study published in the Lancet....
Submit interim safety report: CDSCO panel tells Novartis for phase 3 study of intrathecal OAV-101 Medical Dialogues Team7 Nov 2021 9:30 AM ISTNew Delhi: In a significant development, drug firm Novartis has got a green signal from the Subject Expert Committee (SEC) functional under the...
